Ahead of the staggering changes brought about by the Affordable Care Act (ACA), many predicted that the need for manufacturer-funded Patient Assistance Programs would decline as patients received coverage from new government sources. Now that we are well into the ACA’s implementation, it’s clear how healthcare reform is impacting PAPs. Our latest blog post examines what changed and what hasn’t.
Next week industry leaders from pharma, specialty pharmacies, distributors, and payers will convene at the World Congress Summit on Specialty Market Access and Channel Optimization. The Summit is an opportunity to collaborate on product launch and distribution challenges, as well as best practices.
At last week’s 15th Annual Patient Assistance and Access Programs conference, I joined more than 400 industry experts to discuss the changing landscape of patient assistance. This is a hot topic that we’ve discussed here on the blog. It will continue to receive attention as the regulations are finalized.
There’s a lot of ambiguity around how the government is going to view the private and public exchanges. An OIG opinion providing guidance on whether these plans will be viewed as public versus private plans could have far-reaching implications for how manufacturers provide patient assistance. If we look at some of the OIG guidance offered around Medicare Part D plans and the potential for anti-kickback penalties when offering direct assistance to these beneficiaries, we can start to hypothesize about some of the challenges pharmaceutical manufacturers will face.
The annual Managed Markets Summit is a great opportunity to learn the pharma industry’s ever-changing landscape from its leaders. This year is even more critical in light of the implementation of the Affordable Care Act. The new law is rapidly changing many aspects of healthcare, from reimbursement strategies to emphasizing data-driven care.
Experts from UBC and Express Scripts are joining more than 60 other faculty members at this year’s conference to discuss the impacts of the ACA along with other key trends in the marketplace.
Copay programs may be one of the touchiest topics in the industry. Pharmaceutical Commerce recently published a special report titled “Copay programs' increased value to manufacturers is matched by rising criticism,” which details the issue from a variety of perspectives.
The unknown impact of Healthcare Reform is a hot topic for most manufacturers today. As we all scramble to prepare for multiple scenarios in uncharted territory, expert guidance is no longer considered a luxury. To flourish, much less survive, manufacturers need to dance on the balls of their feet and align with the most trusted advisors.
If changes to the healthcare landscape have you puzzled, you’re not alone. In an environment where there seem to be more questions than answers, our Healthcare Reform experts analyzed new healthcare regulations from a manufacturer perspective and narrowed the plethora of information down to the basics. As your organization plans for the future, our challenge to you is to answer three basic questions:
- What is the potential impact to my market access programs (PAP, copay assistance, alternate funding)?
During ISPOR’s 15th Annual European Congress, held in Berlin, Germany, November 3-7, 2012, UBC will have a strong presence and an influential voice. ISPOR, the International Society for Pharmacoeconomics and Outcomes Research, works to increase the efficiency, effectiveness, and fairness of healthcare to improve health.